Tryptophan hydroxylase 2 (TPH2) is the key enzyme in the synthesis of neuronal serotonin. Although previous studies suggest that TPH2 neuron-restrictive silencer element (NRSE) functions as a negative regulator dependent on neuron-restrictive silencer factor (NRSF) activity, the underlying mechanisms are yet to be fully elucidated. Here, we show a detailed analysis of the NRSE-mediated repression of the human TPH2 (hTPH2) promoter activity in RN46A cells, a cell line derived from rat raphe neurons. Quantitative real-time RT-PCR analysis revealed the expression of serotonergic marker genes (Mash1, Nkx2.2, Gata2, Gata3, Lmx1b, Pet-1, 5-Htt, and Vmat2) and Nrsf gene in RN46A cells. Tph1 mRNA is the prevalent form expressed in RN46A cells; Tph2 mRNA is also expressed but at a lower level. Electrophoretic mobility shift assays and reporter assays showed that hTPH2 NRSE is necessary for the efficient DNA binding of NRSF and for the NRSF-dependent repression of the hTPH2 promoter activity. The hTPH2 promoter activity was increased by knockdown of NRSF, or over-expression of the engineered NRSF (a dominant-negative mutant or a DNA-binding domain and activation domain fusion protein). MS-275, a class I histone deacetylase (HDAC) inhibitor, was found to be more potent than MC-1568, a class II HDAC inhibitor, in enhancing the hTPH2 promoter activity. Furthermore, treatment with the ubiquitinspecific protease 7 deubiquitinase inhibitors, P-22077 or HBX 41108, increased the hTPH2 promoter activity. Collectively, our data demonstrate that the hTPH2 NRSE-mediated promoter repression via NRSF involves class I HDACs and is modulated by the ubiquitin-specific protease 7-mediated deubiquitination and stabilization of NRSF. Keywords: gene expression, NRSF, promoter, serotonergic neuron, TPH2, transcriptional regulation. Address correspondence and reprint requests to Hiroaki Matsui, Department of Molecular and Behavioral Neuroscience, St. Marianna University Graduate School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan. E-mail: h2matsui@marianna-u.ac.jp Abbreviations used: 5-HT, 5-hydroxytryptamine (serotonin); EMSA, electrophoretic mobility shift assay; HBX 41108, 7-chloro-9-oxo-9H-indeno [1,2-b]pyrazine-2,3-dicarbonitrile; MC1568, 3-[5-(3-(3-fluorophenyl)-3-oxopropen-1-yl)-1-methyl-1H-pyrrol-2-yl]-N-hydroxy-2-propenamide; NRSE/RE-1, neuron-restrictive silencer element/repressor element 1; NRSF/REST, neuron-restrictive silencer factor/repressor element 1 silencing factor; P22077, 1-(5-((2, 4-difluorophenyl) thio)-4-nitrothiophen-2-yl) ethanone; PAGE, poly acrylamide gel electrophoresis; RT, reverse transcription; TBE, tris/borate/EDTA buffer; TSS, transcription start site; USP7, ubiquitin-specific protease 7; UTR, untranslated region.
The central serotonin (5-hydroxytryptamine, 5-HT) system, which arises from the midbrain raphe nuclei and is distributed throughout the brain, modulates diverse physiological functions, including regulation of sleep, appetite, memory, and emotion (Jacobs and Azmitia 1992; Muller and Jacobs 2010) . Dysfunction of the 5-HT system in the brain has been implicated in the etiology of a wide range of neurodevelopmental disorders, including depression, anxiety, obsessive-compulsive disorder, autism, and schizophrenia (Lesch and Waider 2012) .
Tryptophan hydroxylase (TPH) mediates the initial and rate-limiting steps in the 5-HT biosynthesis (Lovenberg et al. 1967) . The two TPH enzymes (TPH1 and TPH2) identified are encoded by two distinct genes: TPH1 is mainly expressed in peripheral tissues, such as the pineal gland and enterochromaffin cells in the gastrointestinal tract (Côt e et al. 2003) , whereas TPH2 is primarily expressed in neuronal serotonergic cells in the brain and enteric nervous system (Walther and Bader 2003; Patel et al. 2004; Zhang et al. 2004; Gershon and Tack 2007) . In the human brain, quantitative real-time RT-PCR (qRT-PCR) and immunohistochemistry studies demonstrated abundant expression of TPH2 mRNA and protein in raphe nuclei (Bach-Mizrachi et al. 2006; De Luca et al. 2006; Zill et al. 2007; Gutknecht et al. 2009 ). As the rate-limiting enzyme for the synthesis of central 5-HT, TPH2 plays a pivotal role in the modulation of 5-HT neurotransmission, and is thus a promising target for the therapeutic treatment of neuropsychiatric disorders (Matthes et al.2010; Popova and Kulikov 2010) .
Since TPH2 was identified, much effort has been made to examine the gene for functional variants and to determine whether these variants can be correlated with clinical aspects of neuropsychiatric disorders (Zill et al. 2004; Zhang et al. 2005; Lopez de Lara et al.2007; Cichon et al. 2008; Haghighi et al. 2008; Waider et al. 2011) . However, a limited number of studies on human TPH2 (hTPH2) gene expression regulation have been accomplished.
Examination of the function of hTPH2 gene polymorphisms revealed the 5 0 -untranslated regions (5 0 -UTRs) modulating hTPH2 gene expression (Scheuch et al. 2007; Chen and Miller 2013) . By using serial deletion analysis, the core promoter of hTPH2 gene was localized to the region between nt À107 and +7 (transcription start site is designated as +1) (Chen et al.2008) , which also contains a calcium-responsive element that mediates cell-type-specific induction of hTPH2 gene transcription by calcium mobilization (Lenicov et al.2007) . A recent study using deletion and site-directed mutagenesis identified the estrogen response element half-site located within the hTPH2 promoter that may be important for the estrogen receptor b-induced hTPH2 gene transcriptional activity (Hiroi and Handa 2013) . Patel et al. (2007) found that neuron-restrictive silencer element (NRSE), also known as RE-1 (repressor element 1), is present within the rat TPH2 (rTPH2) promoter region, which can bind to neuron-restrictive silencer factor (NRSF), also known as repressor element 1 silencing factor (REST), and represses the rTPH2 promoter activity. rTPH2 NRSE is evolutionarily conserved but distinguished from the 21 bp canonical NRSE by the presence of a 6 bp insertion in the middle of the motif and is thereby defined as the non-canonical NRSE (Johnson et al. 2007; Otto et al. 2007; Patel et al. 2007) . It is worth noting that the 5 0 -UTR of the hTPH2 gene also contains non-canonical NRSE at the well-conserved position (+9/+35) compared to rTPH2 gene (Patel et al. 2007; Gentile et al. 2012) .
NRSF consists of nine zinc fingers and two repressor domains located at its N-and C-terminals ends (RD1 and RD2), respectively (Chong et al. 1995; Schoenherr and Anderson 1995) . NRSF contains a DNA-binding domain (DBD) that recognizes NRSE in the regulatory region of target genes. Canonical NRSE has a higher affinity for NRSF than non-canonical NRSE, suggesting that tissue-specific function of NRSF may depend on binding to different NRSE (Bruce et al. 2009 ). Once NRSF binds to NRSE in target genes, it acts as a molecular scaffold to recruit several cofactors to its repressor domains (RD1 and RD2). RD1 interacts with mSin3A, and subsequently recruits histone deacetylase complexes (HDAC1, HDAC2, HDAC4, and HDAC5) (Huang et al. 1999; Roopra et al. 2000; Nomura et al. 2005) . Meanwhile, RD2 recruits REST co-repressor 1 (Andres et al. 1999; Sun et al. 2005) . Thus, NRSF can repress target gene expression through the generation of dynamic macromolecular complexes (Ballas and Mandel 2005; Ooi and Wood 2007) .
It has been reported that post-translational control, mediated by ubiquitination and deubiquitination, plays a critical role in regulating protein levels of NRSF (Ballas and Mandel 2005) . During neuronal differentiation, NRSF undergoes proteasomal degradation through Skp1/Cul1/F-box protein b-TrCP (SCF bTrCP ) E3 ubiquitin ligase -mediated ubiquitination (Guardavaccaro et al. 2008; Westbrook et al. 2008) . Huang et al. (2011) identified a critical deubiquitinase, ubiquitin-specific protease 7 (USP7) that can counterbalance NRSF ubiquitination. These studies demonstrated that the net balance between the SCF b-TrCP -mediated ubiquitination and USP7-mediated deubiquitination controls NRSF protein levels, and consequently its biological functions (Huang and Bao 2012) . Recently we have reported that NRSF-mediated repression of the endogenous Tph2 gene transcription was, at least partly, relieved by a decrease in NRSF levels in A1 mes-cmyc (A1-mes) cells, a mouse mesencephalic embryonic cell line (Gentile et al. 2012) . In conjunction with earlier observations of the structural similarities between rodent and human TPH2 promoters (Lenicov et al. 2007; Patel et al. 2007; Chen et al. 2008) , although our results suggest that hTPH2 NRSE functions as a negative regulator dependent on NRSF expression levels, the underlying mechanisms are yet to be fully clarified.
Elucidation of the hTPH2 NRSE-mediated promoter regulation is a prerequisite for in-depth understanding of the neurobiological dysfunction of the central 5-HT system in neuropsychiatric disorders and for innovative drug development for early, effective treatments. To this end, we conducted a detailed functional analysis of the hTPH2 NRSE-mediated promoter regulation via NRSF in a raphe cell model. Because of the lack of human raphe cell models, we used RN46A cells, a neuronal cell line derived from rat raphe neurons (White et al. 1994) , which have been widely used in the field of serotonin research (Rumajogee et al. 2006; Yammamoto et al. 2013) .
Herein, through a combination of transfection analyses, electrophoretic mobility shift assays (EMSAs), and pharmacologic inhibitor studies, we demonstrated that NRSF binds to hTPH2 NRSE, thereby recruiting class I HDACs to critically repress the hTPH2 promoter activity in RN46A cells. Furthermore, we showed that the inhibition of USP7 deubiquitinating activity led to an increase in the hTPH2 promoter activity, providing experimental evidence of the important contribution of USP7 to the hTPH2 gene regulation possibly through the controlling of NRSF levels.
Materials and methods

Oligonucleotides
The sequences of all the PCR primers and oligonucleotides used in this study are provided in Tables S1 and S2 .
Cell cultures RN46A cells (RRID: CVCL_D261) were obtained from Dr. Scott R. Whittemore (University of Louisville, Louisville, KY 40292) and cultured at 33°C (proliferation) or 39°C (differentiation) by the methods described previously (White et al. 1994; Lenicov et al. 2007) . A1-mes cells were cultured as previously reported (Colucci-D'Amato et al. 1999; Gentile et al. 2012) .
qRT-PCR analysis of the serotonergic marker gene expression in RN46A cells Total RNA was prepared from 1 9 10 6 cells using an RNeasy Mini kit with on-column DNase I digestion (Qiagen, Valencia, CA, USA). The first strand of cDNA was synthesized from 5 lg of total RNA using the ReverTra Ace qPCR Master Mix (TOYOBO, Osaka, Japan) in a 50-lL reaction mixture, according to the manufacturer's protocols. In parallel, rat brain total RNA (5 lg; Clontech, Mountain View, CA, USA) was used to obtain the reference cDNA samples. The cDNA samples obtained from 20 ng of total RNA (except for Tph2, 200 ng and Pet-1, 500 ng) were used for qRT-PCR analysis. Reactions were performed in a 20 lL volume (except for Pet-1, 50 lL) with KOD SYBR qPCR Mix (TOYOBO) and 200 nM of each primer using StepOnePlus real-time PCR system (Applied Biosystems, Foster City, CA, USA), according to the manufacturer's instructions. Each sample was run in triplicate. PCR conditions included an initial denaturation of 2 min at 98°C, followed by 45 cycles (except for Tph2 and Pet-1, 50 cycles) of PCR for 10 s at 98°C, 10 s at 60°C (except for 5-Htt and 5-Ht1a, 55°C), and 30 s at 68°C. The relative amount of target mRNA normalized to the endogenous expression of Gapdh (glyceraldehyde 3-phosphate dehydrogenase) was calculated by the Comparative C T method as described previously (Gentile et al. 2012) . Data are expressed as the mean AE standard deviation (SD) of n = 3 separate experiments, each of which was performed in triplicate. Minusreverse transcription and non-template controls were routinely included to eliminate the possibility of genomic contamination or false-positive analyses.
Preparation of reporter gene constructs TPH2-55 containing a 2-kb region (À1850 to +140) of the hTPH2 gene (AC090109), including a wild-type NRSE, and TPH2-9 containing a mutated NRSE were prepared as described previously (Gentile et al. 2012) . To make hTPH2 NRSE mutants, we focused on a critical GG pair in NRSE that is essential for the binding activity (Mori et al. 1992; Johnson et al. 2007; Patel et al. 2007 ). TPH2-55 was used as the template for PCR using QuickChange sitedirected mutagenesis kit (Stratagene, La Jolla, CA, USA) and specific mutation primers, yielding TPH2-9, TPH2-9-2, and TPH2-9-3 (as specified in Fig. 2 ). Specific DNA regions were generated by PCR using KOD DNA polymerase (TOYOBO), appropriate primer pairs (25 pmol each), and genomic DNA (500 ng) as template. Thermal cycling conditions were as described above, except for an extension at 68°C for 3 min. The fragments were digested with designated restriction enzymes, and then cloned into pGL4-Basic to produce rTPH2 (À997/+9) and rTPH2 (À997/+132) (AC099197), mouse TPH2 (mTPH2) (À870/+9) and mTPH2 (À870/+132) (AC153497), human TPH1 (hTPH1) (À2385/+128) (AC055860), rat TPH1 (rTPH1) (À2212/+94) (AC114528), and mouse TPH1 (mTPH1) (À1100/+117) (AC090122) (as specified in Figs 2 and 3).
All constructs were confirmed by restriction enzyme mapping and subjected to DNA sequencing before being used for transfection.
Transient transfection and luciferase assay in RN46A and A1-mes cells Briefly, RN46A cells (6 9 10 5 cells/well) in 6-well plates were cotransfected with 2.0 lg of reporter plasmid having a long insert or the molar equivalent of the reporter plasmid having various lengths of the insert, and phRluc-null vector (0.1 lg) using TransIT-Neural reagent (Mirus, Madison, WI, USA) according to the supplier's protocol. Similarly, A1-mes cells (8 9 10 4 /well) in 24-well plates were co-transfected with 0.25 lg of reporter plasmid having a long insert, and phRluc-null vector (0.01 lg) using TransIT-Neural reagent (Gentile et al. 2012) . The HSV-TK promoter region was deleted from the pGL4.74 [hRluc/TK] vector (Promega, Madison, WI, USA) to generate the phRluc-null vector, which was used to normalize transfection efficiencies. The cells were harvested 48 h after transfection, and luciferase activities were measured using a Dual Luciferase Assay System (Promega) with Lumicounter 700 (Microtec, Chiba, Japan). The luciferase activity of each construct was normalized to that of the pGL4-Basic or TPH2-55 as specified in the figure legends, and data are expressed as the mean AE SD of at least n = 3 separate experiments, each of which was performed in duplicate.
Preparation of nuclear extracts and EMSA The Nuclear Extract Kit (Active Motif, Carlsbad, CA, USA) was used to prepare nuclear extracts from RN46A cells (1 9 10 7 ). For EMSA, nuclear proteins (2.0 lg) were incubated at 4°C for 30 min in a 20 lL reaction containing 10% glycerol, 1 mM dithiothreitol, 50 mM NaCl, 100 mM KCl, 5 mM MgCl 2 , 10 mM Tris-HCl buffer (pH 7.5), 50 lg/mL poly dI-dC (Amersham Biosciences), 50 lg/mL poly dG-dC (Amersham Biosciences, Little Chalfont, UK), and 0.1% NP-40 with or without a 100-fold molar excess of unlabeled competitors.
The 32 P-labeled probe (10 fmol) was then added and the reaction was incubated at 25°C for 30 min. For supershift assays, either anti-NRSF antibody (1.0 or 2.0 lg) (H-290; sc-25398; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or normal rabbit IgG (1.0 or 2.0 lg) was pre-incubated with the nuclear extract (2.0 lg) at 4°C for 3 h before addition of the 32 P-labeled probe. All DNA-protein complexes were resolved by 4.5% native poly acrylamide gel electrophoresis in 0.259 Tris/borate/EDTA buffer (22 mM Tris, 22 mM boric acid, 0.5 mM EDTA, pH 8.3) at 4°C.
Wild-type hTPH2 NRSE double-stranded oligonucleotides (dsONs) (hTPH2 wt, +9/+35) were used as 32 P-labeled probes and/or competitors. Mutant dsONs m1, m2, and m3 corresponded to NRSE mutations of reporter constructs TPH2-9, TPH2-9-2, and TPH2-9-3, respectively (as specified in Fig. 4 ). Wild-type and mutant superior cervical ganglion (SCG) 10 dsONs were synthesized as described by Mori et al. (1992) .
An increase in the TPH2 promoter activity by shRNA-induced knockdown of NRSF The shRNA plasmid-targeting rat NRSF (SureSilencing shRNA plasmid; KR45101N) and the inactive control plasmid were purchased from Qiagen. RN46A cells (8 9 10 5 cells/well) in 6-well plates were co-transfected with TPH2-55 (1.0 lg), the phRlucnull vector (0.1 lg), and either the rat NRSF-specific shRNA (1.0 lg) or the control plasmid (1.0 lg), using TransIT-Neural reagent. The cells were harvested 48 h after transfection and luciferase activity was measured as described above.
Potentiation of TPH2 promoter activity by a dominant-negative NRSF and a VP64-NRSF DBD fusion protein The DNA fragment corresponding to amino acid residues 84-1007 of human NRSF (Naruse et al. 1999; Du et al. 2010 ) was amplified by PCR and cloned into the pCMV-Script (Agilent Technology, Santa Clara, CA, USA) to generate dominant-negative NRSF (dnNRSF) expression vector, pCMV-dnNRSF. The VP64 acidic transactivation domain and human NRSF DBD (amino acid residues 135-456) coding sequences were amplified by PCR using the expression vectors of VP64 and human NRSF, respectively, as templates (Roopra et al. 2000; Imanishi et al. 2009 ). The two fragments were sequentially inserted into the pCMV-Script using EcoRI/HindIII and then HindIII/XhoI sites to obtain pCMV-VP64-NRSF DBD.
RN46A cells (8 9 10 5 cells/well) in 6-well plates were cotransfected with TPH2-55 (1.0 lg), the phRluc-null vector (0.1 lg), and either the empty pCMV-Script (1.0 lg) or pCMV-dnNRSF (1.0 lg) using TransIT-Neural. Similarly, RN46A cells were cotransfected with TPH2-55 (1.0 lg) or TPH2-9 (1.0 lg), the phRlucnull vector (0.1 lg) and either the empty pCMV-Script (1.0 lg) or pCMV-VP64-NRSF DBD (1.0 lg). The cells were harvested 48 h after transfection, and the luciferase activity was measured as described above.
Potentiation of TPH2 promoter activity by inhibition of HDAC and the USP7 RN46A cells (8 9 10 5 cells/well) in 6-well plates were transfected with TPH2-55 (2.0 lg) and the phRluc-null vector (0.1 lg) using TransIT-Neural reagent. Twenty-four hours after transfection, the cells were treated with broad-spectrum class I and II HDAC inhibitors, Trichostatin A (50 nM; Sigma-Aldrich, St. Louis, MO, USA), valproic acid (VA) (1 mM; Wako-Pure Chemicals, Osaka, Japan), or sodium butyrate (NaB) (1 mM; Wako-Pure Chemicals), a class I HDAC preferential inhibitor, MS-275 (5 lM; Sigma-Aldrich), or a class II HDAC inhibitor,
Similarly, 24 h after transfection, the cells were treated with USP7 deubiquitinase inhibitors, 1-(5-((2, 4-difluorophenyl) thio)-4-nitrothiophen-2-yl) ethanone(P22077) (10 or 30 lM; Tocris Cookson) or 7-chloro-9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile (HBX 41108) (5, 10, or 25 lM; Tocris Cookson) dissolved in dimethylsulfoxide. The cells were harvested 48 h after transfection, and luciferase activity was measured as described above.
Statistical analysis
Statistical analyses were performed using Student's t-test or Bonferroni-corrected t-test wherever applicable. Differences were considered significant at p < 0.05.
Results
Expression of 5-HT neuron marker genes and NRSF in RN46A cells RN46A cells have been considered to be an early serotonergic precursor neuronal cell line (White et al. 1994) , with the potential to switch developmental phenotype. However, the molecular signatures of RN46A cells, including the expression of critical transcription factors involved in serotonergic neuronal development and maturation, have not been fully explored yet. We performed qRT-PCR analysis to confirm RN46A cells as a central serotonergic neuron model. At proliferating condition (33°C), RN46A cells expressed mRNA for critical transcription factors involved in serotonergic neurogenesis (Mash1, Nkx2.2, Gata2, and Gata3) and serotonergic differentiation (Lmx1b and Pet-1) (Alenina et al. 2006; Kiyasova and Gaspar 2011; Deneris and Wyler 2012) (Fig. 1a) . RN46A cells expressed mRNA for serotonergic marker proteins, such as Tph2, 5-Htt (Slc6a4), and Vmat2, but not 5-Ht1a (Fig. 1a) . These results indicate that RN46A cells might have their origin in subpopulations of raphe 5-HT neurons that do not express 5-HT 1A receptors (Kiyasova et al. 2013) . Alternatively, the 5-HT 1A receptor gene expression is strongly repressed by Freud-1/CC2D1A (coiled-coil and C2-domain-containing 1A) in RN46A cells, as reported previously (Ou et al. 2003; Lemonde et al. 2004) . Accordingly, RN46A cells did not express Phox2b, an inhibitory transcription factor that suppresses serotonergic neural fate determination (Fig. 1a ) (Alenina et al. 2006) .
As a reference, we verified the expression of Pet-1, Phox2b, 5-Ht1a, and Tph2 in the rat brain, confirming that the qRT-PCR protocols used were appropriate (Fig. 1b) . Apart from Vmat2 mRNA, similar gene expression profiles were observed when RN46A cells were cultured at differentiating conditions (39°C) for 7 days (Fig. 1a) . The expression levels of Vmat2 mRNA remarkably increased after differentiation, suggesting an enhanced vesicular accumulation of 5-HT in differentiated RN46A cells (White et al.1994) . Collectively, serotonergic gene expression profiling supported the notion that RN46A cells were destined to be serotonergic neural cells as reported previously (White et al. 1994; Alenina et al. 2006) and demonstrated that RN46A cells expressed specific serotonergic properties even under proliferating conditions. According to these results, all subsequent experiments were performed with RN46A cells at proliferating conditions.
It is worth noting that Tph1 mRNA expression levels were distinctively higher than those of Tph2 (Fig. 1a) , indicating that Tph2 gene expression might be repressed in RN46A cells by the NRSE-NRSF system, as reported previously (Patel et al. 2007) . Indeed, RN46A cells expressed Nrsf mRNA at both 33 and 39°C (Fig. 1a) . It is conceivable that the NRSE-NRSF system functions to repress Tph2 gene expression in RN46A cells.
Transient transfection assays demonstrated the functional NRSE-mediated repression of promoter activity of human, rat, and mouse TPH2 genes Next, we functionally characterized the NRSE-mediated hTPH2 promoter regulation in RN46A cells. TPH2-55 carrying a wild-type NRSE (5 0 -TTCAGCACCAGGGT TCTGGACAGCGCC-3 0 , +9/+35) (underlined and doubleunderlined sequences indicate the first and second GG pairs, respectively) showed low promoter activity ( Fig. 2a and b) . TPH2-9 carrying a 3-bp (CAC) deletion (disruption of the 5 0 -half of the NRSE motif) and a 2-bp substitution at the first GG pair (disruption of the 3 0 -half of the canonical NRSE motif) (Mori et al. 1992) showed a significant increase in promoter activity of about four times that of TPH2-55 ( Fig. 2a and b) . However, TPH2-9-2 carrying a 2-bp substitution at the first GG pair alone did not show any appreciable increase in the activity ( Fig. 2a and b) . Accordingly, TPH2-9-3 carrying a 2-bp substitution at the second GG pair alone (disruption of the 3 0 -half of the non-canonical NRSE motif) (Patel et al. 2007 ) showed a significant increase in the activity, comparable to that of TPH2-9 ( Fig. 2a and b) . Collectively, these results indicate that the NRSE motif on the hTPH2 gene is indeed non-canonical and represses the hTPH2 promoter activity in NRSF-expressing RN46A cells.
In addition, both rTPH2 (À997/+132) and mTPH2 (À830/ +132) carrying non-canonical NRSE motifs showed low promoter activity comparable to that of TPH2-55 ( Fig. 2c  and d ). Upon deletion of 5 0 -UTR (including non-canonical NRSE) of rat and mouse TPH2 genes, rTPH2 (À997/+9) and mTPH2 (À830/+9), promoter activities showed a significant increase of about five and three times that of respective wildtype constructs, respectively ( Fig. 2c and d) . These results confirmed and extended previous findings, demonstrating the important contribution of the non-canonical NRSE to the regulation of the rat and mouse TPH2 promoter activities (Patel et al. 2007; Gentile et al. 2012) .
Human, rat, and mouse TPH1 promoter activities in RN46A and A1-mes cells qRT-PCR analysis demonstrated that RN46A cells expressed much higher mRNA levels of endogenous Tph1 than those of Tph2 (Fig. 1a) . Previously, we obtained similar results demonstrating that A1-mes cells expressed distinctively higher mRNA levels of endogenous Tph1 than those of Tph2 (Gentile et al. 2012) . No NRSE motifs, either canonical or non-canonical, were found on the human, rat, and mouse TPH1 promoters. TPH1 genes are reasonably relieved of the NRSE-mediated repression of their promoter activities.
Thus, it would be interesting to examine the TPH1 promoter activity by transfection into RN46A or A1-mes cells. hTPH1 (À2385/+128), rTPH1 (2212/+94) and mTPH1 (1100/+117) enhanced promoter activities by about 10, 20, and 25 times that of pGL4-Basic in RN46A cells, respectively ( Fig. 3a and b) . These results well reflected the relatively higher Tph1 mRNA levels revealed by qRT-PCR in RN46A cells (Fig. 1) . In A1-mes cells, rTPH1 (À2212/ +94) and mTPH1 (1100/+117) showed promoter activities of about 13 times that of pGL4-Basic, whereas hTPH1 (À2385/ +128) showed promoter activity of about 2 times that of pGL4-Basic (Fig. 3c ), indicating that rodent TPH1 genes were preferably expressed. These results demonstrated the distinct features of the regulation of the two 5-HT synthesizing enzyme genes: TPH2 gene expression is under strict control of NRSE, whereas TPH1 gene expression appeared Wild-type rat TPH2 (rTPH2) (À997/+132) and mouse TPH2 (mTPH2) (À870/+132) contain NRSE. Deletion mutants rat TPH2 (rTPH2) (À997/+9) and mTPH2 (À870/+9) lack NRSE. (d) Relative luciferase activity in transfected RN46A cells. The data are expressed as the mean AE SD of n = 3 separate experiments.
to be devoid of the NRSE-mediated repressive control in two rodent 5-HT neuron models, RN46A and A1-mes cells.
NRSF binds to NRSE in the hTPH2 gene promoter Next, EMSAs were performed to determine the nature of the nuclear proteins binding to hTPH2 NRSE. Incubation of the 32 P-labeled dsONs corresponding to hTPH2 NRSE (hTPH2 wt) with RN46A nuclear proteins resulted in the formation of a distinct DNA-protein complex (complex II, Fig. 4a, lane  2) . The DNA-protein complex was not observed in the absence of nuclear proteins (Fig. 4a, lane 1) , and its formation was inhibited by the addition of 100-fold molar excess of unlabeled hTPH2 wt (Fig. 4a, lane 3) or the dsONs containing the rat SCG10 NRSE motif (SCG 10 wt) (Fig. 4a,  lane7 ). Molar excesses of unlabeled hTPH2 NRSE mutant dsONs (m1 and m3) corresponding to the efficacious hTPH2 NRSE mutants in functional assays (see Figs. 2a and b) , or SCG 10 mutant dsONs (SCG 10 mut) did not affect the formation of the DNA-protein complex (Fig. 4a, lanes 4 , 6, and 8, respectively). On the contrary, the disabled hTPH2 NRSE mutant dsONs (m2) still inhibited the formation of the DNA-protein complex (Fig. 4a, lane 5) . These results indicate that hTPH2 NRSE, which is required to repress the hTPH2 promoter activity in transient transfection assays, is also indispensable for the binding of RN46A nuclear proteins.
It should be noted that the high molecular weight DNAprotein complex I did not enter the gel, but remained at the top of the gel (Fig. 4a, lane 2) . The formation of complex I was not observed in the presence of hTPH2 wt, m2, or SCG 10 wt dsONs (Fig. 4a, lanes 3, 5, and 7) . Mutant dsONs m1, m3, or SCG10 mut did not inhibit the formation of complex I (Fig. 4a, lanes 4, 6, and 8) . These results imply that complex I was specifically formed along with complex II.
To further investigate the identities of the proteins in the complex, supershift assays were performed using the antibody against NRSF. DNA-protein complex II was almost completely supershifted by anti-NRSF antibody (Fig. 4b, lanes 5 and 6) , and not by normal rabbit IgG (Fig. 4b, lanes 7 and 8) . As complex I formation was apparently not affected by the anti-NRSF antibody (Fig. 4b , compare lane 2 to lanes 7 and 8), the supershifted complex II was probably merged to complex I at the top of the well (Fig. 4b, lanes 5 and 6) . These results demonstrate that NRSF specifically binds to hTPH2 NRSE.
It has been reported that NRSF functions as a scaffold protein, which associates with specific molecules (such as mSin3, HDACs, and REST co-repressor 1), and forms the high molecular weight protein complex involved in the NRSF-mediated gene repression (Ooi and Wood 2007) . Thus, complex I presumably represent a macromolecular complex containing NRSF and its associate protein components.
Knockdown of NRSF increases the activity of the hTPH2 gene promoter
The shRNA plasmids targeting rat NRSF, and a non-specific shRNA plasmid were used to examine the role of the protein in regulating the activity of the hTPH2 promoter in RN46A cells. TPH2-55 promoter activity was significantly higher in RN46A cells co-transfected with rat NRSF-specific shRNA plasmids (No. 1, 1.67-fold; No. 2, 1.56-fold), compared to that in the control shRNA plasmid-transfected cells (n = 3, p < 0.05) (Fig. 5a) . The increase was comparable to that Relative luciferase activity (Fold change) Fig. 3 Promoter activities of the human, rat, and mouse tryptophan hydroxylase 1 (TPH1) genes in RN46A and A1-mes cells.
(a) Schema of the human, rat, and mouse TPH1 promoter-luciferase constructs. Specific DNA regions of the human, rat, and mouse TPH1 genes were cloned into pGL4-Basic, yielding hTPH1 (À2385/+128), rat TPH1 (rTPH1) observed in the NRSE-disrupted mutant TPH2-9 ( Fig. 2a  and b) . These results provide further evidence that the NRSE-NRSF system plays an important role in regulating the hTPH2 promoter activity in RN46A cells.
An increase in the hTPH2 promoter activity by over-expression of dnNRSF and VP64-NRSF DBD fusion proteins Next, we attempted to examine whether the loss of NRSF activity is followed by a derepression of hTPH2 promoter activity either by over-expression of dnNRSF or VP64-NRSF DBD fusion proteins.
When RN46A cells were co-transfected with TPH2-55 and the vector encoding dnNRSF, the promoter activity in cells over-expressing dnNRSF was significantly higher (1.75-fold) than that in mock-transfected control cells (n = 3, p < 0.05), implying that dnNRSF competed with endogenous NRSF at hTPH2 NRSE and de-repressed the promoter activity (Fig. 5b) .
Moreover, we also attempted to displace endogenous NRSF and activate target genes instead of repressing them by over-expression of the VP64-NRSF DBD fusion proteins. VP64-hybrid transcription factor functions as a potent transactivator and retains the binding specificity of wildtype NRSF (Immaneni et al. 2000; Imanishi et al. 2009 ). The promoter activity in cells over-expressing VP64-NRSF DBD was significantly higher (4.2-fold) than that in the mock-transfected control cells (n = 3, p < 0.05), showing TPH2-9 TPH2-9-2 TPH2-9-3 Fig. 4 Neuron-restrictive silencer factor (NRSF) binds specifically to human tryptophan hydroxylase 2 (hTPH2)-neuron-restrictive silencer element (NRSE). (a) An electrophoretic mobility shift assay (EMSA) in which 10 fmol of 32 P-labeled TPH2 wt (+9/+35) was incubated with 2.0 lg of nuclear proteins from RN46A cells. The indicated wt (TPH2 wt and superior cervical ganglion (SCG) wt) and mutant (TPH2-9, TPH2-9-2, TPH2-9-3, and SCG mut) unlabeled competitors were added at a 100-fold molar excess. The protein-DNA complexes were separated by 4.5% poly acrylamide gel electrophoresis (PAGE) and subjected to autoradiography. The positions of specific protein-DNA complex I, complex II (NRSF), non-specific (NS) complexes, and free probe (FP) are indicated. The nucleotide sequences of the wt and mutated competitors are shown (lower panel). Dashed lines and bold letters indicate a 3-bp (CAC) deletion and a 2-bp (GG to TT) substitution, respectively. (b) An EMSA supershift assay in which either anti-NRSF antibody (1.0 or 2.0 lg) or normal rabbit IgG (1.0 or 2.0 lg) was pre-incubated with 2.0 lg of nuclear proteins from RN46A cells before addition of 10 fmol of the 32 P-labeled TPH2 wt. The wt unlabeled competitors (TPH2 wt and SCG wt) were added at a 100-fold molar excess. Protein-DNA complexes were separated by 4.5% PAGE and subjected to autoradiography. The positions of the supershifted complex I, the non-shifted protein-DNA complex II (NRSF), NS, and FP are indicated.
that the VP64-NRSF DBD fusion protein displaced endogenous NRSF at hTPH2 NRSE and activated the promoter activity. Accordingly, over-expression of VP64-NRSF DBD did not influence the promoter activity of the NRSEdisrupted mutant TPH2-9 (Fig. 5c) . These results demonstrated that over-expression of modified versions of NRSF interfered with the repression function of the endogenous NRSF at hTPH2 NRSE, and consequently caused an increase in the hTPH2 promoter activity.
HDAC inhibitors increase the hTPH2 promoter activity NRSF recruits HDACs to its amino-and carboxyl-terminal RDs by which it represses target gene transcription (Ooi and Wood 2007) . To explore the possible involvement of HDACs in the hTPH2 NRSE-mediated gene repression, we examined the effects of HDAC inhibitors on the activity of the hTPH2 promoter.
Trichostatin A (50 nM), a potent and specific inhibitor of HDAC, greatly increased the TPH2-55 promoter activity (33-fold) (Fig. 6a) . Similarly, VA (1 mM) and sodium butyrate (1 mM) brought about a 19.5-and 22.1-fold increase in promoter activity, respectively (Fig. 6a) . These results clearly indicate that HDACs were recruited by the NRSEbound NRSF to repress the hTPH2 promoter activity in RN46A cells.
Next, to determine which class of HDACs participates in the NRSF-mediated hTPH2 promoter repression, we examined the effects of a potent preferential class I HDAC inhibitor, MS275 (5 lM), and a potent selective class II HDAC inhibitor, MC1568 (5 lM), on the hTPH2 promoter activity. The promoter activity in cells treated with MS275 was significantly higher (7.48-fold) than that of vehicletreated cells (n = 3, p < 0.05), whereas MC1568 modestly increased the promoter activity (2.16-fold) (Fig. 6b) . These results imply that class I HDACs are major contributors to the NRSF-mediated hTPH2 promoter repression inRN46A cells.
USP7 inhibitors increase the hTPH2 promoter activity
It has been reported that NRSF undergoes proteasomal degradation through SCF b-TrCP -mediated ubiquitination (Guardavaccaro et al. 2008; Westbrook et al. 2008) . Initially, we speculated that over-expression of b-TrCP, a substrate recognition component of SCF b-TrCP , would increase the hTPH2 promoter activity by accelerating NRSF degradation. However, TPH2-55 promoter activity was not increased by co-transfection with the expression vector encoding human b-TrCP (data not shown). It is noteworthy that USP7, an ubiquitin-specific protease, prevents NRSF degradation through deubiquitination and counteracts SCF bTrCP in regulating NRSF at the post-translational level (Huang and Bao 2012) . We thus hypothesized that the USP7-mediated NRSF deubiquitination might surpass its ubiquitination and consequently, the NRSF protein levels will be maintained in RN46A cells. To test our hypothesis, we examined the effects of USP7 inhibitors, P22077 (Altun et al. 2011) or HBX 41108 (Colland et al. 2009 ), on the hTPH2 promoter activity. The promoter activity in cells treated with P22077 (30 lM) was significantly higher (2.21-fold) than that of vehicle-treated cells (n = 3, p < 0.05) (Fig. 7a) . In addition, HBX 41108 increased the promoter activity in a dose-dependent manner; the activities in cells treated with HBX 41108 (10 lM and 25 lM) were significantly higher (3.20-fold and 7.36-fold, respectively) than that in vehicle-treated cells (n = 3, p < 0.05) (Fig. 7b) . These results imply that the USP7-mediated deubiquitination also critically contributes to the hTPH2 promoter repression through the NRSE-NRSF system in RN46A cells.
Discussion
NRSE was first identified as a silencer element in the 5 0 -flanking regions of neuron-specific genes of SCG10 and type II Na + channel (Kraner et al. 1992; Mori et al. 1992) , but was subsequently shown to regulate many neuronal genes including TPH2 gene (Ballas and Mandel 2005; Ooi and Wood 2007) . Whereas a well-conserved NRSE is found in the TPH2 promoters, no NRSE motifs were found in the TPH1 promoters (Johnson et al. 2007; Otto et al. 2007; Patel et al. 2007) . Previous studies suggest that TPH2 NRSE functions as a negative regulator dependent on NRSF activity, the underlying mechanisms are yet to be fully elucidated (Lenicov et al. 2007; Patel et al. 2007; Chen et al. 2008) . The purpose of this study was to clarify the mechanisms of the NRSE-mediated repression of the hTPH2 promoter activity via NRSF in RN46A cells, an in vitro model for 5-HT neurons. RN46A cells express 5-HT neuron marker genes including Pet-1, a critical determinant of 5-HT neuron identity (Alenina et al. 2006; Kiyasova and Gaspar 2011; Deneris and Wyler 2012) and moreover, Nrsf gene (Fig. 1a) . Notably, the expression levels of Tph2 mRNA are distinctly lower than those of Tph1 mRNA in RN46A cells (Fig. 1a) . These results are in line with our previous observation that the NRSE-mediated repression of the Tph2 gene is responsible for the lower expression levels of Tph2 mRNA compared to those of Tph1 mRNA in NRSFexpressing mouse A1-mes cells (Gentile et al. 2012) . Taken together, our results suggest that RN46A cells are suitable for elucidating mechanisms of the NRSE-mediated repression of the hTPH2 promoter activity via NRSF in 5-HT neurons.
Luciferase reporter assays demonstrated the NRSEmediated repression of the TPH2 promoter activity in RN46A cells (Fig. 2) . These results may provide evidence that the expression of NRSE containing TPH2 gene is negatively controlled and dependent on the NRSF activity in the brain. It was reported that NRSF mRNA expression in dorsal raphe neurons was significantly higher in female subjects affected by major depressive disorder than in matched controls (Goswami et al. 2010) , suggesting that an alteration of NRSF expression may be associated with diminished 5-HT neurotransmission by TPH2 gene repression.
The 5-HT synthesizing activity is the hallmark of RN46A cells. Our qRT-PCR analysis implies that TPH1, and not TPH2, represents TPH activity that has been identified and considered responsible for 5-HT synthesis in RN46A cells (White et al. 1994) .
Although previous studies have reported detectable TPH1 gene expression in raphe neurons of rats (Patel et al. 2004; Malek et al. 2005) , mice (Gundlah et al. 2005) , and humans , a recent systematic analysis of TPH1 and TPH2 gene expression in adult mouse and human brains did not reveal significant TPH1 gene expression in the raphe nucleus of either species (Gutknecht et al. 2009 ). Curiously enough, endogenous Tph1 gene expression was maintained even under differentiating conditions in both RN46A (Fig. 1a) and A1-mes cells (Gentile et al. 2012) , indicating that these two cell lines do not appear to retain constraints affecting the TPH1 gene expression in the raphe nucleus. Luciferase reporter assays demonstrated the remarkable promoter activity of the human, rat, and mouse TPH1 gene constructs in RN46A cells (Fig. 3b ) and A1-mes cells (Fig. 3c) . These results are well correlated with the higher endogenous Tph1 mRNA levels in RN46A (Fig. 1 ) and A1-mes cells (Gentile et al. 2012) . It is still an open question how TPH1 gene expression is negatively regulated in the raphe nucleus. It would be interesting to speculate that TPH1 gene expression would be suppressed by potential repressor factors as in the case of the TPH2 gene repression by the NRSE-NRSF system. Otherwise, potential stimulatory factors for TPH1 gene expression might not be present in the raphe nucleus.
NRSF is well-known to recruit HDACs for its RDs, and form the high molecular weight protein complex involved in the target gene repression (Huang et al. 1999; Naruse et al. 1999; Ooi and Wood 2007) . Thus, the inhibition of HDAC activity is expected to interfere with the NRSF-mediated repression of the hTPH2 promoter activity. Treatment with representative HDAC inhibitors increased hTPH2 promoter activities ( Fig. 6a and b) . Furthermore, MS-275, a class I histone deacetylase (HDAC) inhibitor, was distinctly more potent than MC-1568, a class II HDAC inhibitor, in increasing the hTPH2 promoter activity (Fig. 6c) . These results suggest, for the first time, that NRSF binds to hTPH2 NRSE and recruits class I HDACs, which are critical for the repression of the hTPH2 promoter activity in RN46A cells. In this context, it is intriguing to note that investigators recently reported the association of the altered expression of HDACs with the pathophysiology of mood disorders. They have also reported that infusion of HADC inhibitors into the nucleus accumbens exerts potent antidepressant-like effects in several behavioral assays and at the level of gene expression, suggesting that targeting HDACs with selective inhibitors may provide a novel approach for treating depression (Covington et al. 2009; Hobara et al. 2010) .
It has been reported that the net balance between the SCF b-TrCP -mediated ubiquitination and the USP7-mediated deubiquitination controls NRSF protein levels and consequently its biological functions (Ballas and Mandel 2005; Huang and Bao 2012) . Firstly, we considered that an acceleration of SCF b-TrCP -mediated NRSF ubiquitination, followed by degradation, would increase the hTPH2 promoter activity. However, the hTPH2 promoter activity was not significantly increased by over-expression of human b-TrCP, a critical substrate recognition subunit (data not shown). We inferred from this information that the USP7-mediated NRSF deubiquitination might surpass the SCF b-TrCP -mediated ubiquitination, leading to maintenance of the stability of NRSF in RN46A cells. Expectedly, treatment with USP7 inhibitors, P22077 (Altun et al. 2011) or HBX 41108 (Colland et al. 2009) , increased the hTPH2 promoter activity (Fig. 7) . These results indicate, for the first time, that the USP7-mediated deubiquitination of NRSF critically contributes to the hTPH2 promoter regulation by possibly controlling NRSF stability in RN46A cells. Intriguingly, aberrant signaling of NRSF and its target genes is closely related to the pathophysiology of several neuropsychiatric disorders including schizophrenia (Loe-Mie et al. 2010) and major depressive disorder (Goswami et al. 2010; Otsuki et al. 2010) . In addition, large-scale copy number variation studies have identified intriguing autism spectrum disorders candidate genes including USP7 (Berg and Geschwind 2012) . Based on these results, this study suggests that the NRSE-NRSF system and its dysregulation might be related to the dysregulation of the hTPH2 gene expression, TPH2-dependent 5-HT synthesis, and the subsequent 5-HT neural system functions in the brain. Future studies will further address an important role of the NRSE-NRSF interaction, the post-translational modulation of NRSF stability, and the NRSF-centered epigenetic mechanisms in regulating the hTPH2 gene expression. In summary, the results presented here demonstrate that hTPH2 NRSE mediates the promoter regulation by NRSF in a raphe neuron cell model, RN46A cells, and that the USP7-mediated NRSF deubiquitination is a critical determinant of NRSF stability, thereby regulating the hTPH2 promoter activity. The findings presented here provide fundamental insights into molecular mechanisms underlying the regulation of hTPH2 gene expression in 5-HT neurons.
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